Free Trial
NASDAQ:ABCL

AbCellera Biologics (ABCL) Stock Price, News & Analysis

AbCellera Biologics logo
$2.85 +0.14 (+5.17%)
(As of 12/20/2024 05:40 PM ET)

About AbCellera Biologics Stock (NASDAQ:ABCL)

Key Stats

Today's Range
$2.68
$2.88
50-Day Range
$2.52
$3.15
52-Week Range
$2.34
$6.05
Volume
2.07 million shs
Average Volume
1.77 million shs
Market Capitalization
$841.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.67
Consensus Rating
Moderate Buy

Company Overview

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
40th Percentile Overall Score

ABCL MarketRank™: 

AbCellera Biologics scored higher than 40% of companies evaluated by MarketBeat, and ranked 704th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    AbCellera Biologics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    AbCellera Biologics has only been the subject of 2 research reports in the past 90 days.

  • Read more about AbCellera Biologics' stock forecast and price target.
  • Earnings Growth

    Earnings for AbCellera Biologics are expected to decrease in the coming year, from ($0.59) to ($0.71) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of AbCellera Biologics is -4.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of AbCellera Biologics is -4.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    AbCellera Biologics has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    7.33% of the float of AbCellera Biologics has been sold short.
  • Short Interest Ratio / Days to Cover

    AbCellera Biologics has a short interest ratio ("days to cover") of 7.4.
  • Change versus previous month

    Short interest in AbCellera Biologics has recently increased by 2.01%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    AbCellera Biologics does not currently pay a dividend.

  • Dividend Growth

    AbCellera Biologics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.33% of the float of AbCellera Biologics has been sold short.
  • Short Interest Ratio / Days to Cover

    AbCellera Biologics has a short interest ratio ("days to cover") of 7.4.
  • Change versus previous month

    Short interest in AbCellera Biologics has recently increased by 2.01%, indicating that investor sentiment is decreasing.
  • News Sentiment

    AbCellera Biologics has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for AbCellera Biologics this week, compared to 3 articles on an average week.
  • Search Interest

    Only 14 people have searched for ABCL on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added AbCellera Biologics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, AbCellera Biologics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    28.00% of the stock of AbCellera Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    61.42% of the stock of AbCellera Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about AbCellera Biologics' insider trading history.
Receive ABCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter.

ABCL Stock News Headlines

AbCellera Biologics (NASDAQ:ABCL) Shares Gap Up - Still a Buy?
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
AbCellera Biologics (ABCL) Gets a Buy from Truist Financial
See More Headlines

ABCL Stock Analysis - Frequently Asked Questions

AbCellera Biologics' stock was trading at $5.71 on January 1st, 2024. Since then, ABCL stock has decreased by 50.1% and is now trading at $2.85.
View the best growth stocks for 2024 here
.

AbCellera Biologics Inc. (NASDAQ:ABCL) issued its quarterly earnings results on Monday, November, 4th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by $0.03. The company earned $6.51 million during the quarter, compared to analysts' expectations of $8.95 million. AbCellera Biologics had a negative trailing twelve-month return on equity of 15.73% and a negative net margin of 533.32%.

AbCellera Biologics (ABCL) raised $356 million in an initial public offering on Friday, December 11th 2020. The company issued 23,000,000 shares at a price of $14.00-$17.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets acted as the underwriters for the IPO.

AbCellera Biologics' top institutional investors include Baillie Gifford & Co. (4.38%), UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (1.55%), State Street Corp (0.11%) and Walleye Capital LLC (0.09%). Insiders that own company stock include Holdings Ltd Thermopylae, Veronique Lecault, Andrew Booth and John S Montalbano.
View institutional ownership trends
.

Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that AbCellera Biologics investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), TotalEnergies (TTE) and AUO (AUOTY).

Company Calendar

Last Earnings
11/04/2024
Today
12/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ABCL
Fax
N/A
Employees
586
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.67
High Stock Price Target
$12.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+204.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-146,400,000.00
Net Margins
-533.32%
Pretax Margin
-613.32%

Debt

Sales & Book Value

Annual Sales
$32.96 million
Book Value
$3.97 per share

Miscellaneous

Free Float
212,664,000
Market Cap
$841.79 million
Optionable
Optionable
Beta
0.41
Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (NASDAQ:ABCL) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners